Results 91 to 100 of about 25,234 (166)

Novel insights into SGLT2 inhibitor efficacy in heart failure: A meta-analysis employing win ratio, hazard ratio, and risk ratio. [PDF]

Am Heart J Plus
Nasrollahizadeh A, Javankiani S, Rahmati S, Nasrollahizadeh A, Hakim D, Modin D, Johansen ND, Biering-Sørensen T, Hosseini K.   +8 more
europepmc   +1 more source

Patterns in Prescribing and Predictors of SGLT2 Inhibitor Administration in Patients with Heart Failure and Acute Myocardial Infarction: A Real-World Retrospective Cohort Study. [PDF]

J Clin Med
Suciu IM, Mateoc-Sîrb T, Luca CT, Timar B, Gaiță D.   +4 more
europepmc   +1 more source

Short-Term Laboratory Outcomes of SGLT2 Inhibitor Use in Type 2 Diabetic Patients: A Retrospective Analysis. [PDF]

J Clin Med
AlSudais H, AlSulaiman T, Alotaibi BA, Alshalani A, Almuqrin AM, Albakr RB, Aldali JA.   +6 more
europepmc   +1 more source

Osmotic nephropathy as a potentially underrecognized cause of acute kidney injury during SGLT2 inhibitor therapy: a case report and literature review. [PDF]

CEN Case Rep
Murata A, Tanaka M, Takayoshi M, Matsuyama Y, Sato R, Ishida Y, Teragaki M, Iwanari S, Ikeda M, Takeoka H.   +9 more
europepmc   +1 more source

Comparative efficacy and safety of different SGLT2 inhibitor-based combination strategies in HFrEF: a systematic review and network meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Jiang N, Zhang Y, Tang Y, Tan H.
europepmc   +1 more source

Ketosis and ketoacidosis in hospitalized patients receiving SGLT2 inhibitor therapy. [PDF]

Diabetes Obes Metab
Gao FM, Kishore K, Pandey D, Jahanabadi H, Stevens M, Lecamwasam A, Bellomo R, Churilov L, Ekinci EI.   +8 more
europepmc   +1 more source

Multidisciplinary care: A missing solution to SGLT2 inhibitor underuse in heart failure. [PDF]

ESC Heart Fail
Siddiqui WK.
europepmc   +1 more source

SGLT2 inhibitor-associated euglycemic ketoacidosis after percutaneous coronary intervention for ST-segment elevation myocardial infarction. [PDF]

J Cardiol Cases
Kuno T, Amanai S, Takama N, Ishii H.
europepmc   +1 more source

Novel insights into the hepatoprotective mechanisms of SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats. [PDF]

Front Pharmacol
Comella F, Aragón-Herrera A, Melini S, Opallo N, Feijóo-Bandín S, Navatti NP, Mattace Raso G, Gualillo O, Pirozzi C, Lago-Paz F, Meli R.   +10 more
europepmc   +1 more source

Efficacy and safety of SGLT2 inhibitor empagliflozin in T2DM with established cardiovascular disease: a systematic review and meta-analysis of RCTs. [PDF]

Ann Med Surg (Lond)
Abunada O, Hassan F, Kumar N, Kumar S, Majeed I, Batra K, Kumar D, Deepika D, Turesh M, Ashraf T, Hyder S, Suresh KN, Kumar L, Kumar S, Kamlesh F, Yusuf SA.   +15 more
europepmc   +1 more source